Technical Analysis for DYAI - Dyadic International, Inc.

Grade Last Price % Change Price Change
F 1.06 0.00% 0.00
DYAI closed unchanged on Friday, November 1, 2024, on 21 percent of normal volume.
Earnings due: Nov 6
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Inside Day Range Contraction 0.00%
20 DMA Resistance Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Gapped Up Strength 0.00%
20 DMA Resistance Bearish 0.95%

   Recent Intraday Alerts

Alert Time
Possible Inside Day about 17 hours ago
10 DMA Resistance about 20 hours ago
Up 2% about 20 hours ago
Up 1% about 20 hours ago
Reversed from Up 2 days ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Dyadic International, Inc. Description

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Additionally, and more recently, Dyadic is also beginning to explore the use of its C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of Adeno-associated viral vectors (AAV) and certain metabolites. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Natural Sciences Pharmacy Antibodies Medication Monoclonal Antibodies Vaccines Gene Expression Healthcare System Biosimilar Fusion Protein

Is DYAI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.67
52 Week Low 0.9257
Average Volume 24,183
200-Day Moving Average 1.47
50-Day Moving Average 1.18
20-Day Moving Average 1.10
10-Day Moving Average 1.08
Average True Range 0.08
RSI (14) 43.50
ADX 12.59
+DI 16.99
-DI 19.56
Chandelier Exit (Long, 3 ATRs) 0.99
Chandelier Exit (Short, 3 ATRs) 1.22
Upper Bollinger Bands 1.18
Lower Bollinger Band 1.03
Percent B (%b) 0.22
BandWidth 14.14
MACD Line -0.03
MACD Signal Line -0.03
MACD Histogram 0.0
Fundamentals Value
Market Cap 30.54 Million
Num Shares 28.8 Million
EPS -0.23
Price-to-Earnings (P/E) Ratio -4.61
Price-to-Sales 13.45
Price-to-Book 5.20
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.14
Resistance 3 (R3) 1.14 1.11 1.12
Resistance 2 (R2) 1.11 1.09 1.11 1.12
Resistance 1 (R1) 1.09 1.08 1.10 1.09 1.11
Pivot Point 1.06 1.06 1.07 1.06 1.06
Support 1 (S1) 1.04 1.04 1.05 1.03 1.01
Support 2 (S2) 1.01 1.03 1.01 1.00
Support 3 (S3) 0.99 1.01 1.00
Support 4 (S4) 0.98